Background
Coronavirus disease‐2019 (COVID‐19) has spread all over the world and brought extremely huge losses. At present, there is a lack of study to systematically analyze the features of hydroxybutyrate dehydrogenase (α‐HBDH) in COVID‐19 patients.
Methods
Electronic medical records including demographics, clinical manifestation, α‐HBDH results and outcomes of all included patients were extracted.
Results
α‐HBDH in COVID‐19 group was higher than that in excluded group (
p
< 0.001), and there was no significant difference in α‐HBDH before and after the exclusion of 5 patients with comorbidity in heart or kidney (
p
= 0.671). In COVID‐19 group, the α‐HBDH value in ≥61 years old group, severe group, and critical group, death group all increased at first and then decreased, while no obvious changes were observed in other groups. And there were significant differences of the α‐HBDH value among different age groups (
p
< 0.001), clinical type groups (
p
< 0.001), and outcome groups (
p
< 0.001). The optimal scale regression model showed that α‐HBDH value (
p
< 0.001) and age (
p
< 0.001) were related to clinical type.
Conclusions
α‐HBDH was increased in COVID‐19 patients, obviously in ≥61 years old, death and critical group, indicating that patients in these three groups suffer from more serious heart and kidney and other tissues and organs damage, higher α‐HBDH value, and risk of death. The difference between death and survival group in early stage might provide a approach to judge the prognosis. The accuracy of the model to distinguish severe/critical type and other types was 85.84%, suggesting that α‐HBDH could judge the clinical type accurately.
Background: To characterize C-reactive protein (CRP) changes features from patients with coronavirus disease 2019 (COVID-19) and to quantify the correlation between CRP value and clinical classification.
Methods: This was a bidirectional observational cohort study. All laboratory confirmed COVID-19 patients hospitalized in Xiangyang No.1 People's Hospital were included. Patients' general information, clinical type, CRP value and outcome were collected. Patients were grouped according to the age, clinical type and outcome, and their CRP were compared. The CRP value, age gender, and clinical type were used to build a categorical regression model to investigate the association between CRP and clinical type.
Results: The 131 patients aged 50.13 plus-or-minus 17.13 years old. There were 4 mild, 88 moderate, 21 severe and 18 critical cases. Statistical significance of CRP median exists between different clinical types and ages. There were 10 deaths and 121 cases have been discharged. The CRP in death group dramatically increased continuously until died, while increased firstly and decreased later in the survivor and survivor in critical type. The categorical regression model also showed that CRP and age had significant coefficient. During the first 15 days from symptom onset, the maximum of CRP ranged between 0.47-53.37 mg/L were related to mild combined with moderate type, ranged 53.84-107.08 mg/L were related to severe type, and 107.42-150.00 mg/L were related to the critical type.
Conclusions: CRP showed different distribution feature and existed differences in various ages, clinical types and outcomes of COVID-19 patients. The features corresponded with disease progression.
The serum PCT level can be used as an early diagnostic indicator of infection after internal fixation for traumatic fracture. The combined use of PCR and CRP levels can increase the sensitivity of detection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.